From Yahoo Finance: 2025-06-11 20:06:00

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is deemed a top biotech stock with a buy rating and $44 price target under Stifel’s coverage. The company focuses on obicetrapib, a CETP inhibitor for cardiovascular disease treatment, showing promise in the lipid-lowering market. Stifel sees significant upside potential despite cautious commercial assumptions.

Obicetrapib differentiates itself in the CETP inhibitor market through NewAmsterdam Pharma’s cardiovascular outcomes trial, PREVAIL. Stifel’s $44 price target reflects confidence in the drug’s unique clinical profile and market prospects. The company’s approach to market access and impending regulatory milestones position it for growth in the competitive biotech landscape.



Read more at Yahoo Finance: NewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at Stifel